書籍詳細

[I] 骨代謝マーカー研究の現状と将来展望

P.11 掲載の参考文献

• 1) Garnero, P., Grimaux, M., Seguin, P., Delmas, P. D.:Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9:255-264, 1994
  pubmed

• 2) 川口浩, 松本俊夫, 黒川高秀ほか:Monoclonal 抗体を用いたtwo-site immunoradiometric assay (IRMA) による血清BGP濃度の測定. ホルモンと臨床38:1291-1296, 1990

• 3) Szulc, P., Chapuy, M-C., Meunier, P. J., Delmas, P. D. et al.:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91:1769-1774, 1993
  pubmed

• 4) Melkko, J., Niemi, S., Risteli, L. et al.:Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36:1328-1332, 1990
  pubmed

• 5) Seyedin, S. M., Kung, V. T., Daniloff, Y. N. et al.:Immunoassay for urinary pyridinoline:the new marker of bone resorption. J. Bone Miner. Res. 8:635-641, 1993
  pubmed

• 6) Garnero, P., Shih, W. J., Gineyts, E., Delmas, P. D. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. Endocrinology 79:1693-1700, 1994

• 7) Thiede, M. A., Smock, S. L., Petersen, D. N. et al.:Presence of messenger ribonucleic acid encoding osteocalcin, a marker of bone turnover, in bone marrow megakaryocytes and peripharal blood platelets. Endocronology 135:929-937, 1994

[II] コラーゲン代謝

P.22 掲載の参考文献

• 1) (コラーゲン全般に関しては次の成書を参照されたい) 藤本大三郎編:細胞外マトリックスのバイオサイエンスとバイオテクノロジー. アイピーシー, 1990 Bittar, E. E, Kleinman, H. K. eds.:Extracellular Matrix (Advances in Mol. Biol. and Cell Biol. vol 6), JAI Press, 1993

• 2) Fujimoto, D., Moriguchi, T., Ishida, T. et al.:The structure of pyridinoline, a collagen crosslink. Biochem. Biophys. Res. Commun. 84:52, 1978
  pubmed

• 3) Ogawa, T., Ono, T., Kawanishi, Y.:A novel fluor in insoluble Collagen:A crosslinking moiety in collagen molecule. Biochem. Biophys. Res. Commun. 107:1252, 1982
  pubmed

• 4) Eyre, D. R., Knoob, T. J., Van Ness, K. P.:Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal. Biochem. 137:380, 1984

• 5) Yamauchi, M, London, R. E, Guenat, C. et al.:Structure and formation of a stable histidine-based trifunctional crosslink in skin collagen. J. Biol. Chem. 262:11428, 1987
  pubmed

• 6) Fujimoto, D., Suzuki, M, Uchiyama, A. et al.:Analysis of pyridinoline, a cross-linking compound of collagen fibers, in human urine. J. Biochem. 94:1133, 1983
  pubmed

• 7) Eyre, D. R.:New biomarkers of bone resorption. J. Clin. Endocrinol. Metab. 74:470A, 1992

• 8) Risteli, J., Elomaa, I., Niemi, S. et al.:Radioimmunoassay for the pyridinoline crosslinked carboxy-terminal telopeptide of type I collagen:A new marker of bone collagen degradation. Clin. Chem. 39:635, 1993
  pubmed

• 9) Bettica, P., Baylink, D. J., Moro, L.:Galactosyl hydroxylysine and deoxypyridinoline:Amethodological comparison. Eur. J. Clin. Chem. Clin. Biochem. 31:459, 1993

[III] 骨代謝マーカーと骨形態計測

P.30 掲載の参考文献

• 1) Harris, W. H., Heaney, R. P.:Skeletal rene wal and metabolic bone disease. N. Engl. J. Med. 280:193-211, 1969

• 2) Frost, H. M.:Tetracycline-based histological analysis of bone remodeling. Calcif Tisue Res. 3:211-218, 1969

• 3) Hosoda, K, Kanzaki, S., Eguchi, H. et al.:Secretion of osteocalcin and its propeptide from human osteoblastic cells:Dissociation of the secretory patterns of osteocalcin and its propeptide. J. Bone Miner. Res. 8:553-564, 1993
  pubmed

• 4) Garnero, P., Shih, W. J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994
  pubmed

• 5) Atkinson, P. J.:Changes in resorption spaces in femoral cortical bone with age. J. Pathol. Bacteriol. 89:173-178, 1965

• 6) Merz, W. A., Schenk, R. K.:Aquantitative histological study on bone formation in human cancellous bone. Acta Anat. 76:1-15, 1970

• 7) Guy, J. A., Shea, M., Peter, C. P. et al.:Continuous alendronate treatment throughout growth, maturation, and aging in the rat results increases in bone mass and mechanical properties. Calcif Tissue Int. 53:283-288, 1993
  pubmed

• 8) Katsumata, T., Nakamura, T., Ohnishi, H. et al.:Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomizedrats. J. Bone Miner. Res. 10:921-931, 1995

[IV] 骨代謝マーカーの測定とその意義

P.41 掲載の参考文献

• 1) Garnero, P., Gineyts, E., Riou, J. P. et al.:Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 79:780-785, 1994
  pubmed

• 2) Schlemmer, A., Hassager, C., Risteli, J. et al:Possible variation in bone resorption during the normal menstrual cycle. Acta Endocrinol. 129:388-392, 1993
  pubmed

• 3) Blumsohn, A., Herrington, K., Hannon, R. A. et al.:The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Metab. 79:730-735, 1994
  pubmed

• 4) Schlemmer, A., Hassager, C., Pedersen, B. J. et al.:Posture, age, menopause, and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. J. Bone Miner Res. 9:1883-1888, 1994

• 5) Garnero, P., Grimaux, M, Seguin, P. et al.:Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9:255-264, 1994
  pubmed

• 6) Risteli, J., Elomaa, I., Niemi, S. et al.:Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen:anew serum marker of bone collagen degradation. Clin. Chem. 39:635-640, 1993

• 7) Szulc, P., Chapuy, M.-C., Meunier, P. J. et al.:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91:1769-1774, 1993
  pubmed

• 8) Duda, R. J., O'brien, J. F, Katzmann, J. A. et al.:Concurrent assays of circulating bone gla-protein and bone alkaline phosphatase:effects of sex, age, and metabolic bone disease. J. Clin. Endocrinol. Metab. 66:951-957, 1988
  pubmed

P.49 掲載の参考文献

• 1) Moss, D. W.:Alkaline phosphatase isoenzymes. Clin. Chem. 28:2007-2016, 1982
  pubmed

• 2) Van Hoof, V. O., Hoylaerts, M. F., Geryl, H. et al.:Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis. Clin. Chem. 36:875-878, 1990
  pubmed

• 3) Robison, R.:XXXIII The possible significance of hexosephosphric esters in ossification. Biochem. J. 17:286-293, 1923

• 4) Ali, S. Y., Sajdera, S. W., Anderson, H. C.:Isolation and characterization of calcifying matrix vesicles from epiphyseal cartilage. Proc. Natl. Acad. Sci. USA 67:1513-1520, 1970
  pubmed

• 5) Matsuzawa, T., Anderson, H. C.:Phosphatases of epiphyseal cartilage studied by electron microscopic cytochemical methods. J. Histochem. Cytochem. 12:801-808, 1971
  pubmed

• 6) Masuhara, K., Sugamoto, K, Yoshikawa, H. et al.:Purification of bone alkaline phosphatase from human osteosarcoma. Bone Miner. 3:159-170, 1987

• 7) Moss, D. W.:Electrophoresis of human alkaline and acid phosphatases. Clin. Lab. Med. 6:507-523, 1986
  pubmed

• 8) Moss, D. W., Whitby, L G.:Asimplified heatinactivation method for investigating alkaline phosphatase isoenzymes in serum. Clin. Chem. Acta 61:63-71, 1975

• 9) Mulivor, R. A., Mennuti, M., Zackai, E. H. et al.:Prenatal diagnosis of hypophosphatasia:Genetic, biochemical and clinical studies. Am. J. Hum. Genet. 30:271-282, 1978
  pubmed

• 10) Seargeant, L. E., Stinson, R. A.:Evidence that three structural genes code for human alkaline phosphatases. Nature 281:152-154, 1979
  pubmed

• 11) Weiss, M. J., Ray, K., Henthorn, P. S., Harris, H. et al.:Structure of the human liver/bone/kidney alkaline phosphatase gene. J. Biol. Chem. 263:12002-12010, 1988

• 12) Terao, M., Studer, M., Gianni, M. et al.:Isolation and characterization of the mouse liver/bone/kidney-type alkaline phosphatase gene. Biochem. J. 268:641-648, 1990
  pubmed

• 13) Rosalki, S. B., Foo, A. Y.:Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. Clin. Chem. 30:1182-1186, 1984
  pubmed

• 14) Behr, W., Barnert, J.:Quantification of bone alkaline phosphatase in serum by precipitation with wheat germ lectin:a simplified method and its clinical plausibility. Clin. Chem. 32:1960-1966, 1986
  pubmed

• 15) Lawson, G. M, Katzmann, J. A., Kimlinger, T. K. et al.:Isolation and preliminary characterization of monoclonal antibody that interacts preferentially with the liver isoenzyme of human alkaline phosphatase. Clin. Chem. 31:381-385, 1985
  pubmed

• 16) Bailyes, E. M., Seabrook, R. N, Calvin, J. et al.:The preparation of monoclonal antibodies to humanbone and liver alkaline phosphatase and their use in immunoaffinity purification and in studying these enzymes when present in serum. Biochem. J. 244:725-733, 1987

• 17) Hill, C. S., Wolfert, R. L:The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin. Chim. Acta 186:315-320, 1989
  pubmed

• 18) Masuhara, K, Yoshikawa, H., Takaoka, K. et al.:Monoclonal antibody against human bone alkaline phosphatase. Int. Orthop. 15:61-64, 1991

• 19) Goseki, M., Oida, S., Sasaki, S.:Detection of minor immunological differences among human"universal-type"alkaline phosphatases. J. Cell. Biochem. 38:155-163, 1988
  pubmed

• 20) Masuhara, K., Suzuki, S., Yoshikawa, H., Takaoka, K. et al.:Development of a monoclonal antibody specific for human bone alkaline phosphatase. Bone, Miner. 17:182-186, 1992
  pubmed

• 21) Nagoya, S., Ueda, T., Wada, T. et al.:Detection of bone-type alkaline phosphatase by monoclonal antibodies reacting with human osteosarcoma-associated antigen. Jpn. J. Cancer Res. 82:862-870, 1991

• 22) Morris, D. C., Masuhara, K., Takaoka, K. et al.:Immunolocalization of alkaline phosphatase in osteoblasts and matrix vesicles of human fetal bone. Bone Miner. 19:287-298, 1992

• 23) Randall, J. C, Morris, D. C., Zeiger, S., Masuhara, K. et al.:Presence and activity of alkaline phosphatase in two human osteosarcoma cell lines. J. Histochem. Cytochem. 37:1069-1074, 1989
  pubmed

• 24) Jemmerson, R, Fishman, W. H.:Convenient selection of monoclonal antibodies to isoenzymes of placental alkaline phosphatase using the catalytic activity of the antigen in enzyme-antigen immunoassay. Anal. Biochem. 124:286-292, 1982
  pubmed

• 25) Muller, K, Schellenberger, V., Borneleit, P. et al.:The alkaline phosphatase from bone:transphosphorylating activity and kinetic mechanism. Biochim. Biophys. Acta 1076:308-313, 1991
  pubmed

• 26) Weinreb, M., Shinar, D., Rodan, G. A.:Different pattem of alkaline phosphatase, osteopontin, and osteocalcin expression in developing rat bone visualized by in situ hybridization. J. Bone Miner. Res. 5:831-842, 1990

• 27) Franceschi, R. T., Young, J.:Regulation of alkaline phosphatase by 1, 25-dihydroxyvitamin D3 and ascorbic acid in bone-derived cells. J. Bone Miner. Res. 5:1157-1167, 1990

• 28) Zernik, J., Twarog, K., Upholt, W. B.:Regulation of alkaline phosphatase and alpha2 (1) procollagen synthesis during early intramembranous bone formation in the rat mandible. Differentiation 44:207-215, 1990

• 29) Henthorn, P. S., Rasucha, M., Fedde, K. N. et al.:Different missense mutations at the tissue-nons-pecific alkaline phosphatase gene locus in autosomal recessively inherited forms of mild and severe hypophosphatasia. Proc. Natl. Acad. Sci USA 89:9924-9928, 1992

• 30) Schwartz, M. K.:Enzymes in cancer. Clin. Chem. 19:10-22, 1973

P.59 掲載の参考文献

• 1) Hauschka, P. V., Lian, J. B, Gallop, P. M.:Direct identification of the calcium-binding amino acid, γ-carboxyglutamate, in mineralized bone. Natl. Acad. Sci. USA 72:3925-3929, 1975

• 2) Price, P. A., Otuka, A. S., Poser, J. W. et al.:Characterization of a γ-carboxyglutamic acid containing protein from bone. Proc. Natl. Sci. Acad. USA 73:1447-1451, 1976

• 3) Huq, N. L., Rambaud, S. M., Teh, L. C. et al.:Immunochemical detection and characterization of osteocalcin from moa. Biochem. Biophys. Res. Commun. 129:714-720, 1985
  pubmed

• 4) Stenflo, J., Fernlund, P., Egan, W. et al.:Vitamin K-dependent modification of glutamic acid rezidues in prothrombin. Proc. Natl. Sci. Acad. USA 71:2730-2733, 1974

• 5) Price, P. A., Williamson, M. K., Haba, T. et al.:Excessive mineralization with growth plate closure in rats on chlonic warfarin treatment. Proc. Natl. Sci. Acad. USA 79:7734-7738, 1982

• 6) Sprenger, J. W., Opitz, J. M., Bidder, U.:Heterogeneity of chondrodysplasia punctata. Humangenetik 11:190-212, 1971

• 7) Thiede, M. A., Smock, S. L., Peterson, D. N. et al.:Presence of messenger ribonucleic acid encoding osteocalcin, a maker of bone turnover, in bone megakaryocyte and peripheral blood plateletes. Endocrinlogy 135:929-937, 1994

• 8) Mundy, G. R., Poser, J. W.:Chemotactic activity of the γ-carboxyglutamic acid containining protein in bone. Calcif Tissue Int. 35:164-168, 1983

• 9) Gallop, P. M, Lian, J. B., Hauschka, P. V.:Carboxylated calcium-binding proteins and vitamin K. N Engl. J. Med. 302:1460-1466, 1980
  pubmed

• 10) Price, P. A., Nisimoto, S. K.:Radioimmuoassay of the Vitamin K-dependent protein of bone and its discovery in plasma. Proc. Natl. Acad. Sci. USA 77:2234-2238, 1980

• 11) Price, P. A., Parthemore, J. B., Deftos, L. H.:New biochemical marker for bone metabolism. J. Clin. Invest. 66:878-833, 1980

• 12) Price, P. A., Baukol, S. A.:1, 25-dihydroxy Vitamin D? increases serum levels of Vitamin K-dependent synthesis of the Vitamin K-dependent bone protein. Biochenz. Biophys. Res. Commun. 99:928-935, 1981

• 13) Hauschka, P. V., Lian. J B., Cole, D. E. et al.:Osteocalcin and matrix gla protein:Vitamin-K dependent protein in bone.Physiol. Rev. 69:990-1047, 1989
  pubmed

• 14) Lian, J. B., Gundberg, C. M.:Osteocalcin:Biochemical considerations and clinical applications. Clin. Orthop. 226:267-291, 1988
  pubmed

• 15) Price, P. A.:Vitamin K-dependent formation of bone gla proteins (osteocalcin) and its function. Vitamines and Hormones 42:65-108, 1985

• 16) Price, P. A.:Role of vitamin K-dependent proteins in bone metabolism. Ann. Rev. Nutr. 8:565-583, 1988

• 17) Kasai, R., Yamamuro, T., Okumura, H. et al.:Statistical analysis of age-and sex-rerated changes of serum osteocalcin. J. Bone Miner. Met. 11:7-16, 1993

• 18) Kasai, R., Yamamuro, T., Okumura, H. et al.:Osteocalcin and pro-osteocalcin as potential biochemical and pathological markers in human osteosacroma. Fontiers of Osteosacroma Research. (Novak, J. F., McMaster, J. H. eds.) Honrefe & Huber Publishers, 1993, pp. 229-232

• 19) Malluche, H. H., Faugere, M. C, Fanti, P. et al.:Plasma levels of bone Gla-protein on chronic maintenance dialysis. Kindney Int. 26:869-874, 1984

• 20) Iwasaki, R., Yamamuro, T., Okumura, H. et al.:Immunohistochemical study of bone GLA protein in primary bone tumors. Cancer 70:619-624, 1992
  pubmed

• 21) 笠井隆一, 山室隆夫, 奥村秀雄ほか:Bone Gla Protein (Osteocalcin) および bone Gla protein 前駆体の免疫組織, 細胞学的局在の検討整形・災害外科33:1269-1276, 1990

• 22) Celeste, A. V., Rosen, V., Buecker, J. L. et al.:Isolation of the human for bone GLA protein utilizing mouse and rat cDNA clones. EMBO J. 5:1885-1890, 1986

• 23) Ohta, S., Yamamuro, T., Lee, K. et al.:Fracture healing induces expression of the proto-oncogene cfos in vivo. Possible involvement of the Fos protein in osteoblastic differentiation. FEBS 284:42-45, 1991
  pubmed

• 24) Kasai, R., Bianco, P., Robey, P. G. et al.:Production and characterization of an antibody against the human bone GLA protein (BGP/osteocalcin) propeptide and its use in immunocytochemistry:of bone cells. Bone Miner. 25:167-182, 1994
  pubmed

• 25) Hosoda, K., Kanzaki, S., Eguchi, H. et al.:Secretion of osteocalcin and its propeptide from human osteoblast cells:Dissociation of the secretory patterns of osteocalcin and its propeptide. J. Bone Miner. Res. 8:553-562, 1993
  pubmed

• 26) Gundberg, C. M., Mary, E C.:The osteocalcin propeptide is not secreted in vivo or in vitro. J. Bone Miner. Res. 7:73-80, 1992
  pubmed

• 27) Gundberg, C. M., Weinsein, R. S.:Multiple immunoreactive forms of osteocalcin in uremic serum J.Clin. Invest. 77:1762-1767, 1986

• 28) Hosoda, K, Eguchi, H., Kubota, T. et al.:Asandwich immunoassay for intact human osteocalcin. Clin. Chem. 38:2233-2238, 1992

• 29) Szulc, M. C, Chapuy, M. C, , Meunier, J. et al.:Serum undecarboxylated osteocalcin is a marker of the risk of hip fracture in erderly women. J. Clin. Invest. 91:1769-1774, 1993

• 30) Hart, J. P., Shearer, M. J., Klenerman, L. et al.:Electrochemical detection of depressed circulation levels of vitamin K in osteoporosis. J. Clin. Endoclin. Metab. 60:1268-1269, 1985

• 31) Morrison, N. A., Qi, J C., Tokita, A. et al.:Prediction of bone density from vitamin D recepter alleles. Natzare 357:284-287, 1994

• 32) Parthemore, J. G., Bruton, D. W., Deftos, L. J.:Associations and dissociation between serum bone Gla protein and alkaline phosphatase in skeletal metabolism. J. Orthop. Res. 11:671-676, 1993

P.70 掲載の参考文献

• 1) Martin, GR, Byers, P. H., Piez, K. A.:Procollagen. Adv. Enaymol. 42:167-191, 1975
  pubmed

• 2) Prockop, D. J., Kivirikko, K. I., Tuderman, L. et al.:The biosynthesis of collagen and its disorders. N Engl. J. Med. 301:13-23, 1979
  pubmed

• 3) Merry, A. H., Harwood, R., Wooley, D. E. et al.:Identification and partial characterization of the collagenous arnino-and carboxyl-terminal extension peptides of cartilage procollagen. Biochem. Biophys. Res. Common. 71:83-90, 1970

• 4) Miyahara, M., Njieha, F. K, Prockop, D. J.:Formation of collagen fibrils in vitro by cleavage of procollagen with procollagen proteinases. J. Biol. Chem 257:8442-8448, 1983

• 5) Taubman, M. B., Goldberg, R., Sherr, C. J.:Radioimmunoassay for human procollagen. Science 186:1115-1117, 1974

• 6) Smedsrod, B., Melkko, J., Risteli, J. et al.:Circulating C-terminal propeptide of type 1 procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 271:345-350, 1990
  pubmed

• 7) Taylor, A. K., Kraenzlin, M., Baylink, D. J.:In:Osteoporosis update 1978. (Genant, H. K. ed.) University of Califomia Printing Services, San Francisco, 1987, pp. 19-27

• 8) Carey, D. E., Goldberg, B., Ratzan, S. K. et al.:Radioimmunoassay for type I procollagen in growth hormone-deficient children before and during treatment with growth hormone. Pediatr. Res. 19:8-11, 1985

• 9) Taubman, M. B., Kammerman, S., Goldberg, B.:Radioimmunoassay of procollagen in serum of patients with Paget:s disease of bone. 1) roc. Soc. Exp. Biol. Med. 152:284-287, 1976

• 10) Simon, L S., Krane, S. M., Wortman, P. D. et al.:Serum levels of type I and III procollagen fragments in Paget:s disease of bone. J. Clin. Endocrinol. Metab. 58:110-120, 1984
  pubmed

• 11) Melkko, J., Niemi, S., Risteli, J. et al:Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36:1328-1332, 1990
  pubmed

• 12) 幸田久平:ヒトI型 procollagen C 末端peptide の抽出・精製とその radioimmunoassay 法による肝線維化の診断肝臓 25:192-203, 1984

• 13) 中塚喜義, 関谷喜一郎, 吉田博昭ほか:骨・カルシウム代謝異常における血清I型プロコラーゲンC末端ペプチドの測定―骨代謝回転の指標としての臨床的有用性の検討. 日骨代謝誌10:173-180, 1992

• 14) Nakatsuka, K., Miki, T., Nishizawa, Y. et al.:Characteristics of biochemical markers for bone formation in the elderly. J. Bone Mener. Met. 10:145-151, 1992

• 15) Hassager, C., Resteli, J., Risteli, L. et al.:Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 7:1307-1311, 1992
  pubmed

• 16) 福永仁夫, 大塚信昭, 小野志磨人ほか:I型プロコラーゲンC末端プロペプタイド (PICP) 測定用キットによるその血中濃度の測定. 腎と骨代謝6:237-244, 1993

• 17) Parfit, A. M., Simon, L. S., Villanueva, A. R. et al.:Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkalinephosphatase. J. Bone Miner. Res. 2:427-436, 1987

• 18) Eriksen, E. F, Charles, P., Melsen, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease:Correlation with bone histomorphometry. J. Bone Miner. Res. 8:127-137, 1993
  pubmed

• 19) 芳賀賀介, 成高義彦, 大石俊法ほか:消化器癌患者における血清P-1-P測定の臨床的意義について―CEA, CA-19-9との比較検討. 医学と薬学24:1047-1053, 1990

• 20) Hasling, C., Eriksen, E. F., Melkko, J. et al.:Effects of a combined estrogen-gestagen regimen on serum levels of carboxy-terminal propeptide of human type I procollagen in osteoporosis. J. Bone Miner. Res. 6:1295-1300, 1991

• 21) Resch, H., Pietschmann, P., Pernecker, B. et al.:The influence of partial gastrectomy on biochemical parameters of bone metabolism and bone density. Clin. Investig. 70:426-429, 1992
  pubmed

• 22) Francini, G., Gonnelli, S., Petrioli, R. et al.:Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol. Biomarfeer Prev. 2:125-129, 1993
  pubmed

• 23) Garnero, P., Smith, W. J., Gineyts, Eet al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994

• 24) Nakatsuka, K., Miki, T., Nishizawa, Y. et al.:Intact molecules of bone Gla-protein in patients with abnormal bone and calcium metabolism. J. Bone Miner. Met. 10:152-161, 1992

• 25) Ebeling, P. R., Peterson, J. M., Riggs, B. L.:Utility of type I procollagen propeptide assay for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 7:1243-1250, 1992
  pubmed

• 26) 三浦裕晃, 山本逸雄, 游逸明ほか:骨代謝マーカーと骨量減少予測. Osteoporosis Japan 3:342-344, 1995

• 27) Alvarez, L, Guanabens, N, Peris, P. et al.:Discriminative value of biochemical markers of bone tumover in assessing the activity of Paget:s disease. J. Bone Miner. Res. 10:458-465, 1995

• 28) Simon, L S., Krane, S. M., Wortman, P. D. et al.:Serum Ievels of type I and III procollagen fragments in Paget:s disease of bone. J. Clin. Endocrino. Metab. 58:110-120, 1984

• 29) Li, F., Iqbal, J., Wassif, W. et al.:Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int. 55:90-93, 1994
  pubmed

• 30) Ebeling, P. R.:Role of novel biochemical markers of bone turnover. Osteoporosis 1:3-4, 1994

• 31) Braham, H., Ljungggren, O., Larsson, K. et al.:Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen. Calczf Tissue. Int. 55:412-416, 1994

• 32) 片桐誠, 大多和孝博, 福永仁夫ほか:腎性上皮小体機能元進症における骨代謝マーカー検討:PICPとICTP測定の意義腎と骨代謝8:231-237, 1995

• 33) Gram, J., Bollerslev, J., Nielsen, H. K. et al:Increased serum concentration of type I procollagen c-terminal peptide and osteocalcin during a short course of calcitriol abministration to adult male volunteers. Acta Endocrinol. 125:609-613, 1991

• 34) Sorva, A., Risteli, J., Risteli, L. et al.:Effects of vitamin D and calcium on markers on bone metabolism in geriatric patients with low serum 25-hydroxyvitamin D levels. Calci Tissue Int. (suppl) 49:S88-S89, 1991

• 35) Komm, B. S., Terpening, C. M., Benz, D. J. et al:Estrogen binding, receptor mRNA and biologic response in osteoblast osteosarcoma cells. Science 241:81-86, 1988
  pubmed

P.81 掲載の参考文献

• 1) Lam, K. W., Li, C. Y., Yam, L T. et al.:Comparison of prostatic and nonprostatic acid phosphatase. Ann. N. Y. Acad. Sci. 390:1-15, 1982
  pubmed

• 2) Abdul-Fadal, M. A. M., Kings, E. J.:Properties of the acid phosphatase of erythrocyte and the human prostata gland. Biochemistry 45:51-60, 1946

• 3) Lam, K. W., Lai, L C., Yam, L. T.:Tartrate-resistant (Band 5) acid phosphatase activity measured by electrophoresis on acrilamide gel. Clin. Chem. 23:89-94, 1977

• 4) Lam, K. W., Eastlund, D. T., Li, C. Y.:Biochemical properties of tartrate-resistant acid phosphatase in serum of adults and children. Clin. Chem. 24:1105-1108, 1978

• 5) Yam, L T., Li, C. Y., Law, K W.:Tartrate-resistant acid phosphatase isozyme in the reticulum cells of leukemia reticuloendotheliosis. N. Engl. J. Med. 284:357-360, 1971

• 6) Hammarstorm, L. E, Hanker, J. S., Toverud, S. U.:Cellular differences in acid phosphatase isozyme in bone and teeth. Clin. Orthop. 78:151-167, 1971

• 7) Minkin, C.:Bone acid phosphatase:Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 34:285-290, 1982
  pubmed

• 8) Stepan, J. J., Zichova, M., Lachmanova, J. et al.:Plasma tartrate-resistant acid phosphatase;as a marker for osteoclastic bone resorption. Acta Univ. Carol. Med. 32:345-353, 1986
  pubmed

• 9) Lau, K. H. W., Kraenzlin, M. E., Onishi, T. et al.:Develpment of an improved assay for tartrateresistant acid phosphatase (TrACP) in serum:Potential use to assess bone resorption. In Osteoporosis I 1987. Osteooress Kobenhavn. (Christiansen, C. et al. eds.) Denmark, 1987, pp. 682-687

• 10) 大西泰文:血清酒石酸抵抗性酸性フォスファターゼ活性測定に関する研究. 日大医誌49:904-911, 1990

• 11) Lam, K. W., Siemens, M., Sun, T. et al.:Enzyme immunoassay for tartrate-resistant acid phosphatase. Clin. Chem. 28:467-470, 1982
  pubmed

• 12) Echetebu, Z. O., Cox, T. M., Mass, D. W. et al.:Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. Clin. Chem. 33:1832-1836, 1987

• 13) Cheung, C. K., Panesar, N. S., Masarei, D. R. L. et al.:Purification and the development of an immunoassay for tartrate-resistant acid phosphatase and its use in monitoring bone metabolism. Proc XV Congress of IFCC. Clin. Biochenz. Rev. 14:318, 1993

• 14) Kraenzlin, M. E., Lau, K. H., Liang, L. et al.:Development of all immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J. Clin. Endocrinol. Metab. 71:442-451, 1990
  pubmed

• 15) 中塚喜義, 三木隆己, 西沢良記ほか:慢性腎不全患者における血清酒石酸抵抗性酸フォスファターゼ活性測定の臨床的意義. 骨と骨代謝4:301-310, 1991

• 16) Scarnecchia, L, Minisola, S., Pacitti, M. T. et al.:Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scαnd, J. Clin. Lab. Invest. 51:517-524, 1991

• 17) Chen, J., Yam, L. T., Janckila, A. J. et al.:Clinical significance "high" acid phosphatase activity in the serum of normal children. Clin. Chem. 25:719-722, 1979

• 18) Stepan, J. J, Tesarova, A., Havranek, T. et al.:Age and sex dependency of the biochemical indices of bone remodeling. Clin. Chim. Acta 151:273-283, 1985
  pubmed

• 19) Schiele, F., Artur, Y., Floc:h, A. Y. et al.:Total, tartrate-resistant, and tartrate-inhibited acid phosphatase in serum:Biological variation and reference limits. Clin. Chem. 34:685-690, 1988
  pubmed

• 20) 中塚喜義, 三木隆己, 西沢良記ほか:代謝性骨疾患における血清酒石酸耐性酸フォスファターゼ活性測定の臨床的意義. 日骨代謝誌7:239, 1989

• 21) Rico, H., Villa, L. F.:Serum tartrate-resistant acid phosphatase (TRAP) as a biochemical marker of bone remodeling. Calcif Tissue. Int. 52:149-150, 1993
  pubmed

• 22) Torres, R., de Ia Piedra, C., Rapado, A.:Clinical usefulness of serum tartrate-resistant acid phosphatase in Paget:s disease of bone:Correlation with other biochemical markers of bone remodelling. Calcif Tissue Int. 49:14-16, 1991

• 23) Revilla, M., Iritia, M, Arribas, I. et al.:Tartrate-resistant acid phosphatase as biological marker of bone modelling and turnover in women in relation to their gonadal state. J. Obstet. Gynecol. 12:191-194, 1992

• 24) de la Piedra, C., Torres, R, Rapado, A. et al.:Serum tartrate-resistant acid phosphatase and bone mineral content in postmenopausal women. Calcif Tissue Int. 45:58-60, 1989
  pubmed

• 25) Stepan, J. J., Pospichal, J., Presl, J. et al.:Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone 8:279-284, 1987
  pubmed

• 26) Nakatsuka, K., Miki, T., Nishizawa, Y. et al.:Characteristics of biochemical for bone formation in the elderly. J. Bone Miner. Met. 10:145-151, 1992

• 27) Stepan, J. J., Pospichal, J., Schreiber, V. et al.:The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen and norethisterone. Calcif Tissue Int. 45:273-280, 1989
  pubmed

• 28) Cheung, C. K, Panesar, N. S., Lau, E. et al.:Increased bone resorption and decreased bone formation in Chinese patients with hip fracture. Calcif Tissue Int. 56:347-349, 1995
  pubmed

• 29) Rico, H., Revilla, M., Iritia, M. et al.:Total body bone mineral and tartrate-resistant acid phosphatase levels in type I and III osteogenesis imperfecta. Miner. Electololyte Metab. 17:396-398, 1991
  pubmed

• 30) Stepan, J. J., Silinkova-Malkova, E, Havranek, T. et al.:Relationship of plasma tartrate resistant acid phosphatase to bone isoenzyme of serum alkalinephosphatase in hyperparathyroidism. Clin. Chim. A cta 133:189-200, 1983

• 31) Stepan, J. J., Lachmanova, J., Starakova, M. et al.:Serum osteocalcin, bone alkaline phosphatase and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone Miner. 3:177-183, 1987

• 32) Nakatsuka, K., Miki, T., Shoji, S. et al.:Serum intact molecule of bone Gla-protein in patients with abnormal bone and calcium metabolism. J. Bone Miner. Met. 10:152-161, 1992

• 33) Lam, K. W., Dannaher, C., Letchford, S. et al.:Tartrate-resistant acid phosphatase in serum of cancer patients. Clin. Chem. 30:457-459, 1984
  pubmed

• 34) Tavassoli, M., Rizo, M., Yam, L. T.:Elevation of serum acid phosphatase in cancers with bone metastasis. Cancer 45:2400-2403, 1980
  pubmed

• 35) Desoize, B., Amico, S., Larbre, H. et al.:Phosphatase isoenzymes as bone metastasis markers in prostatic carcinome. Clin. Biochem. 24:443-446, 1991

• 36) Frankel, E. P., Toortellote, C. E.:Elevated serum acid phosphatase associated with multiple myeloma. Arch. Intern. Med. 110:345-349, 1962

• 37) Cosman, F., Nieves, J., Herbert, J. et al.:High-dose glucocorticoid in multiple sclerosis patients exert derect effects on the kidney and skeleton. J. Bone Miner. Res. 9:1097-1105, 1994

P.92 掲載の参考文献

• 1) Prockop, D. J., Kivirikko, K. I.:Treatise on Collagen. 1968, pp. 215-246

• 2) Prockop, D. J., Kivirikko, K. I., Tuderman, K.:The biosynthesis of collagen and its disorders. N. Engl. J. Med. 301:13-23, 1979

• 3) 織田弘美:骨コラーゲン代謝の基礎と代謝マーカーとしての可能性. 日骨代謝誌10:99, 1992

• 4) 長野敬, 吉田賢右:ローン生化学. 医学書院, 1991, p. 87

• 5) Kivirikko, K. I.:Excretion of urinary hydroxyproline peptide in the assessment of bone collagen deposition and resorption. In:Clinical Disorders of Bone and Mineral Metabolism. (Frame, B., Potts, J. T. Jr. eds.) Excerpta Medica, Amsterdam, 1983, pp. 105-107

• 6) Lowry, M., Hall, D. E, Brosnan, J. J.:Hydroxyproline metabolism by the rat kidney:Distribution of renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine. Metabolism 39:955, 1985

• 7) Reid, K. B. M, Lowe, D. M., Porter, R. R.:Isolation and characterization of Clq, a subcomponent of the first component of complement, from human and rabbit sera. Biochem. J. 130:749-763, 1972

• 8) Reid, K. B. M.:Acollagen-like amino acid sequence in a polypeptide chain of human Clq (a sub-component of the first component of complement). Biochem. J. 141:189-203, 1974

• 9) Krane, S. M., Kantrowitz, F. G., Byrne, M.:Urinary excretion of hydroxylysine and its glycosides as an index of collagen degradation. J. Clin. Invest. 59:819-827, 1977
  pubmed

• 10) Paroni, R., Vecchi, De., Fermo, I. et al.:Total urinary hydroxyproline determined with rapid and simple high-performance liquid chromatography. Clin. Chem. 38:407-411, 1992

• 11) Nakamura, T., Nagai, Y., Yamato, H.:Regulation of bone turnover and prevention of bone atrophy in ovariectomized beagle dogs by the administration of 24R, 25 (OH) 2D3. Calcif Tissue Int. 50:221-227, 1992
  pubmed

• 12) Bettica, P., Moro, L, Robins, S. P.:Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin. Chem. 38:2313-2318, 1992
  pubmed

• 13) Platt, W. D., Doolittle, L H., Hartshorn, J. W. S.:Urinary hydroxyproline excretion in metastatic cancer of bone. N. Engl. J. Med. 271:287-290, 1964

• 14) 西野治身, 田中明子, 梶田悦子ほか:中高年女性における骨代謝指標の相互関連-尿中ハイドロキシプロリンと血清中骨型アルカリフォスファターゼの検討. 富山衛研年報15:156-157, 1992

• 15) Cunningham, L. W., Ford, J. D., Segrest, J. P:The isolation of identical hydroxylysyl glycosides from hydroxyrates of soluble collagen and from human urine. J. Biol. Chem. 242:2570-2571, 1967
  pubmed

• 16) Askenasi, R.:Urinary hydroxylysine and hydroxylysyl glycoside excretions in normal and pathologic states. J. Lab. Clin. Med. 83:673-679, 1974

• 17) 吉原一博, 高橋克明, 持留成年ほか:ヒドロキシリジン配糖体の尿中排泄レベルの日内・日間変動, 並びに排泄レベルに及ぼす蛋白質摂取の影響の検討. 衛生化学39:589-593, 1993

• 18) Moro, L, Pozzi, M. R, Gazzarrini, C.:Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int. 42:87-90, 1988

• 19) Yoshihara, K, Mochidome, N, Hara, T.:Urinary excretion levels of hydroxylysine glycosides in osteoporotic patients. Biol. Pharm. Bull. 17:836-839, 1994
  pubmed

• 20) Bettica, P., Baylink, D. J., Moro, L.:Galactosyl hydroxylysine and deoxypyridinoline:amethodological comparison. Eur. J. Clin. Chem. Clin. Biochem. 31:459-465, 1993

P.101 掲載の参考文献

• 1) Fujimoto, D., Akiba, K., Nakamura, N.:Isolation and characterization of a fluorescent material in bovine achilles tendon collagen. Biochem. Biophys. J. Res. Commun. 76:1124-1129, 1977

• 2) Ogawa, T., Ono, T., Tsuda, M. et al.:Anovel fluor in insoluble collagen;A crosslinking moiety in collagen molecule. Biochem. Biophys. Res. Commun. 107:1252-1257, 1982

• 3) Eyre, D. R., Koob, T. J., Van Ness, K. P.:Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. J. Anal. Biochem. 137:380-388, 1984

• 4) Hoshino, H., Takahashi, M., Kushida, K. et al.:Quantitation of the crosslinks, pyridinoline, deoxypyridinoline and pentosidine, in human aorta with dystrophic calcification. Atherosclerosis 112:39-46, 1995
  pubmed

• 5) Pyridinium crosslinks as markers of bone resorption. Lancet 340:278-279, 1992
  pubmed

• 6) Prockop, D. J.:Isotopic studies on collagen degradation and the urine excretion of hydroxyproline. J. Clin. In vest. 43:453-460, 1964

• 7) Colwell, A., Eastell, R., Assiri, A. M. A. et al.:Effect of diet on deoxypyridinoline excretion. (Christiansen, C., Overgaard, K. eds.) Osteoporosis 1990:proceedings of the Third International Symposium on Osteoporosis, October 14-20, 1990. Aalborg, Denmark:Aalborg Stiftstrykkeri, 1990, pp. 590-591

• 8) Fujimoto, D., Suzuki, M., Uchiyama, A. et al.:Analysis of pyridinoline, a crosslinking compound of collagen fibers, in human urine. J. Biochem. 94:1133-1136, 1983
  pubmed

• 9) Black, D., Dunkan, A., Robins, S. P.:Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal. Biochem. 169:197-203. 1988

• 10) Takahashi, M., Ohishi, T., Aoshima, H. et al.:Prefractionation with cation exchanger for determination of intermolecular crosslinks, pyridinoline and pentosidine, in hydrolysate. J. Liq. Chromatogr. 16:1355-1370, 1993

• 11) 高橋正哲:尿中ピリジノリンとデオキシピリジノリン. 検査と技術23:84-85, 1995

• 12) Eyre, D.:New biomarkers of bone resorption. J. Clin. Endocrinol. Metab. 74:470 A-470 C, 1992

• 13) Pratt, D. A., Daniloff, Y., Duncan, A. et al.:Automated Analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Anal. Biochem. 207:168-175, 1992
  pubmed

• 14) Eriksen, E. F., Charles, P., Melsen, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease:Correlation with bone histomorphometry. J. Bone Miner. Res. 8:127-132, 1993
  pubmed

• 15) Hanson, D. A., Weis, M. A., Bollen, A. M. et al.:Aspecific immunoassay for monitoring human bone resorption;Quantitation of type I collages cross-linked N-telopeptide in urine. J. Bone Miner. Res. 7:1251-1258, 1992

• 16) Seyedin, S. M., Kung, V. T., Daniloff, Y. N. et al.:Immunoassay for urinary pyridinoline:The new marker of bone resorption. J. Bone Miner. Res. 8:635-641, 1993
  pubmed

• 17) Robins, S. P., Woitge, H., Hesley, R. et al.:Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9:1643-1649, 1994
  pubmed

• 18) Garnero, P., Gineyts, E, Arbault, P. et al.:Different effects of bisphosphonate and estrogen therapy on free and peptide-bound cross-links excretion. f, Bone Miner. Res. 10:641-649, 1995

• 19) Kamel, S., Brazier, M., Picard, C. et al.:Urinary excretion of pyridinolines crosslinks measured by immunoassay and HPLC techniques in normal subjects and in elderly patients with vitamin D deficiency. Bone Miner. 26:197-208, 1994
  pubmed

• 20) Schlemmer, A., Hassager, C., Jensen, S. B. et al.:Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J. Clin. Endocrinol. Metab. 74:476-480, 1992
  pubmed

• 21) Eastell, R., Calvo, M. S., Burrit, M. F. et al.:Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J. Clin. Endocrinol. Metab. 74:487-494, 1992

• 22) Ohishi, T., Takahashi, M., Kawana, K. et al.:Age related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. Clin. Invest. Med. 16:319-325, 1993
  pubmed

• 23) 高橋正哲, 大石強, 串田一博ほか:尿中ピリジノリン, デオキシピリジノリンの健常者および骨粗髪症患者における測定値. The Bone 7:61-67, 1993

• 24) Uebelhart, D., Shelemmer, A., Johansen, J. S. et al.:Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 72:367-373, 1991

• 25) Hassager, C., Colwell, A., Assiri, A. M. A. et al.:Effect of menopause and hormone replacement therapy on urinary excretion of pyridinium crosslinks;Alogitudinal and cross-sectional study. Clinical. Endocrinol. 37:45-50, 1992

• 26) Kawana, K., Kushida, K., Takahashi, M. et al.:The effect of menopause on biochemical markers and ultrasound densitometry in healthy females. Calcif. Tissue Int. 55:420-425, 1994
  pubmed

• 27) Robins, S. P., Black, D., Paterson, C. R.:Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur. J. Clin. Invest. 21:310-315, 1991
  pubmed

• 28) Seibel, M. J., Gartenberg, F., Silverberg, S. J. et al.:Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 74:481-486, 1992
  pubmed

• 29) Ohishi, T., Kushida, K., Takahashi, M. et al.:Urinary bone resorption makers in patients with metabolic bone disorders. Bone 15:15-20, 1994

• 30) Body, J. J., Delmas, P. D.:Urinary pyridinium cross-links an markers of bone resorption in tumor-associated hypercalcemia. J. Clin. Endocrinol. Metab. 74:471-475, 1992
  pubmed

• 31) 高橋正哲, 大石強, 川名幸一ほか:悪性腫瘍に伴う高カルシウム血症患者において尿中ピリジノリン, デオキシピリジノリンを測定した1例. 整形外科44:1792-1793, 1993

• 32) Harvey, R. D., Mchardy, K. C., Reid, I. W. et al.:Measurement of bone collagen degradation in hyperthyroidism and during tyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J. Clin. Endocrinol. Metab. 72:1189-1194, 1991

• 33) Ohishi, T., Takahashi, M., Kushida, K et al.:Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism. Endocr:Res. 10:281-290, 1992

• 34) Lipton, A., Demers, L, Daniloff, Y. et al.:Increased urinary excretion of pyridinium cross-links in cancer patients. Clin. Chem. 36:614-618, 1993

• 35) Sano, M. Kushida, K., Takahashi, M. et al.:Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br. J. Cancer 70:701-703, 1994
  pubmed

• 36) McLaren, A M., Hordon, L. D., Bird, H. A. et al.:Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann. Rheum. Dis. 51:648-651, 1992
  pubmed

• 37) Garnero, P., Shin, W. J., Gineyts, E. et al.:Comparison of new markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994

• 38) 高橋正哲, 串田一博, 井上哲郎:軟骨代謝マーカー. 尿中コラーゲン架橋. THE BONE 8 (4):81-85, 1994

• 39) Garnero, P., Grimanx, M., Seguin, P. et al.:Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9:225-264, 1994

P.111 掲載の参考文献

• 1) Risteli, J., Elomaa, L, Niemi, S. et al.:Radioimmunoassay for pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen:anew serum marker of bone collagen degradation. Clin. Chem. 39:635-640, 1993

• 2) Eriksen, E. F., Charles, P., Melson, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease. Correlation to bone histomorphometry. J. Bone Miner. Res. 8:127-132, 1993

• 3) Elomaa, I., Virkkunen, P., Risteli, L. et al.:Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer 66:337-341, 1992
  pubmed

• 4) Kylmala, T., Tammela, T., Risteli, L. et al.:Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish prostate cancer group. Eur. J. Cancer 29A:821-825, 1993.
  pubmed

• 5) 山本逸雄, 高田政彦, 游逸明ほか:I型コラーゲンのピリジノリン架橋C端蛋白 (ICTP) の血中濃度の測定. 核医学30:1411-1417, 1993

• 6) 関根恭一, 堀江均, 畠啓視ほか:蛍光検出高速液体クロマトグラフィによる尿中ピリジノリンおよびデオキシピリジノリンの定量. 臨床科学21:367-372, 1992

• 7) Alexandersen, P., Schlemmer, A., Riis, B. J. et al.:Circadian variation in "CrossLaps":anew marker of bone resorption. J Bone Minez Res. 9 (suppl. 1):S190, 1994

• 8) Delmas, P D.:骨代謝マーカー. 開発と臨床応用の最前線. Osteoporosis Jap. 3:3-15, 1995

P.116 掲載の参考文献

• 1) Hanson, D. A., Weis, M. A. E., Bollen, A. M. et al.:Aspecific immunoassay for monitoring human bone resorption:Quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7:1251-1258, 1992

• 2) Clemens, J. D., Herrick, M., Singer, F. R.:Cross-linked N-telopeptides of type I collagen in human serum as a biochemical marker of bone resorption. J. Bone Miner. Res. 9 (suppl. 1):A 522, 1994

• 3) Bollen, A. M., Eyre, D. R.:Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 15:31-34, 1994
  pubmed

• 4) Dresner-Pollak, R., London, D., Greenspan, S. L.:Circadian rhythm of bone milleral metabolism in elderly. J. Bone Miner. Res. 9 (suppl. 1):40, 1994

• 5) Blumsohn, A., Herrington, K., Hannon, R. A. et al.:The Effect of Calcium S upplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Melab. 79:730-735, 1994

• 6) Brenner, R. E, Vetter, U, Bollen, A. M. et al.:Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J. Bone Miner. Res. 9:993-997, 1994
  pubmed